$LRCX

BRANDT ERIC sold $20.0M of LRCX

BRANDT ERIC sold 54,500 shares of LAM RESEARCH CORP (LRCX) at an average of $367.18 ($355.71–$373.09, $20.01M total) across 17 trades on 2026-06-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · BRANDT ERIC
Published Jun 15, 2026, 11:33 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 15, 2026, 11:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LRCX
Neutral
medium confidence
Mentioned
$LRCX
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LRCXNeutralLow
01

Why it matters

A director’s open-market sale totaling ~$20.0M could slightly pressure sentiment, but the presence of a 10b5-1 plan typically lowers interpretive weight versus discretionary selling.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone does not introduce new fundamental information.

03

What to watch

The article provides only the sale details; it does not include any concurrent buys, changes in guidance, or new company fundamentals that would drive a stronger repricing.

Relevance 6/10Novelty 5/10Timing: Filed 2026-06-15; transaction dated 2026-06-12.

Background

The article is an SEC Form 4 insider transaction disclosure for LAM RESEARCH CORP (LRCX).

Company-level read

Ticker impact

$LRCXNeutralMedium confidence
Context

SEC Form 4 shows LRCX director BRANDT ERIC sold about 54,500 shares in an open-market sale under a 10b5-1 plan.

Expected impact

Likely limited/short-lived impact; any move would be more sentiment-driven than fundamental.

Evidence & confidence

The filing is a routine insider transaction with a pre-arranged 10b5-1 plan; no new operational, financial, or regulatory facts are disclosed.

Market effects

Minimal; this is company-specific insider activity with no sector-wide catalyst described.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • LAM RESEARCH CORP

    Subject of the SEC Form 4 insider transaction disclosure.

  • BRANDT ERIC

    Director who sold shares in an open-market transaction under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LRCXMed

The Memory Crunch Is Bigger Than Expected. 1 Top Stock to Buy on the Dip (Hint: Not Micron or Sandisk)

Lam Research (LRCX) is benefiting from a memory chip supply crunch, with revenue up 26% and earnings up 39% in fiscal 2026. The company expects 52% revenue growth and 71% earnings growth in the current quarter. Deloitte projects memory manufacturer capex to rise significantly, favoring Lam's semiconductor equipment sales. Analysts forecast 62% EPS growth for fiscal 2027, with potential for further upside.

$LRCXMedAI 8/10

Ministry approves Lam Research's NT$9.8 billion Taiwan investment

Taiwan's Ministry of Economic Affairs approved Lam Research's NT$9.835 billion (US$310 million) investment in its Taiwan subsidiary for semiconductor equipment R&D. Other approved investments include Zhen Ding Technology's NT$3 billion in Boardtek Electronics, Nuvoton's 15 billion yen in its Japan unit, and Foxconn's US$57.01 million in Mitsubishi Fuso Bus.